Loading
Dermatology and Skin Diseases · Journal article
Allergy · September 4, 2026
Encouraging direction, but not yet definitive.
This Phase II trial demonstrates that pre-seasonal GNR-127 vaccine at 80 μg dose produces a statistically significant 24.13% reduction in combined symptom-medication score compared to placebo, accompanied by a 20-fold increase in Bet v 1-specific IgG and reduced basophil sensitivity. The result is encouraging but represents early efficacy evidence requiring Phase III confirmation, with limitation imposed by single-blind design and modest absolute clinical improvement.
Stage 1: open-label Phase I dose escalation; Stage 2: single-blind, placebo-controlled Phase II randomized trial. Stage 1: 18 participants receiving three escalating doses to determine tolerability. Stage 2: 132 randomized patients with birch pollen allergy receiving pre-seasonal treatment course.. Intervention: GNR-127 recombinant birch pollen allergy vaccine (AB-PreS fusion protein: allergen-derived peptides fused to hepatitis B virus PreS surface protein) at 40 μg or 80 μg dose, aluminum-hydroxide-adsorbed, administered subcutaneously monthly f…. Compared with: Placebo (composition not specified). n = 132. Not stated in source.
80 μg dose produced statistically significant 24.13% dose-dependent reduction in combined symptom medication score over placebo 40 μg dose showed 17.41% reduction over placebo but did not reach statistical significance 80 μg dose induced median 20-fold increase in Bet v 1-specific IgG
Acceptable safety profile maintained despite high administered doses
The 24% absolute reduction in symptom-medication score at the highest dose represents a clinically meaningful improvement for birch pollen allergic patients, though achieved in a single-blind design. Clinicians should view this as promising early-phase evidence warranting Phase III investigation rather than a basis for immediate adoption.
Phase II single-blind RCT showing statistically significant improvement in combined symptom-medication score at 80 μg dose with robust immunological response, but limited by single-blind design, modest effect size, and need for Phase III confirmation.
As stated by the source record.
Quoted from the source exactly as published.
The 24% absolute reduction in symptom-medication score at the highest dose represents a clinically meaningful improvement for birch pollen allergic patients, though achieved in a single-blind design. Clinicians should view this as promising early-phase evidence warranting Phase III investigation rather than a basis for immediate adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT Background We have recently reported the preclinical characterization of a recombinant birch pollen allergy vaccine based on a fusion protein, AB ‐ PreS, consisting of allergen‐derived peptides fused to the hepatitis B virus ( HBV )‐derived PreS surface protein as immunological carrier. Objective To investigate in a clinical study the usefulness of the AB ‐ PreS vaccine, termed GNR ‐127, for allergen‐specific immunotherapy of birch pollen allergy. Methods Stage 1 of the study, an open‐label Phase I study, determined among three doses (20 μg: n = 6; 40 μg: n = 6; 80 μg: n = 6) administered as Aluminum‐hydroxide‐adsorbed vaccines subcutaneously five times in monthly intervals, the highest tolerated doses. In the following Stage 2, randomized patients (placebo: n = 45; 40 μg: n = 43; 80 μg: n = 44) received in a single‐blind, placebo‐controlled Phase II study monthly up to five pre‐seasonal injections. Safety monitoring followed the Medical Dictionary for Regulatory Activities (MedDRA); efficacy parameters were determined according to the European Academy for Allergy and Clinical Immunology ( EAACI ) guidelines; allergen‐specific antibodies and basophil sensitivity were determined by ELISA and basophil activation testing, respectively. Results A dose‐dependent reduction of the combined symptom medication score ( CSMS ) (40 μg: 17.41%; 80 μg: 24.13%) over placebo was observed which was significant for the 80 μg group and accompanied by the strongest induction of Bet v 1‐specific IgG (median 20‐fold increase) and a blunting of the seasonally boosted IgE response and basophil sensitivity. The vaccine showed an acceptable safety profile despite high administered doses. Conclusion A pre‐seasonal course of 5 monthly injections of GNR ‐127 80 μg improved symptoms of birch pollen allergy accompanied by a robust Bet v 1‐specific IgG response, paving the road for a Phase III efficacy study. Trial Registration ClinicalTrials.gov (Identifier: NCT07155499)
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.